Statistical analysis plan of PROWESS SHOCK study by  et al.
The PROWESS SHOCK Steering
Committee
B. Taylor Thompson
V. Marco Ranieri
Simon Finfer
Philip S. Barie
Jean-Francois Dhainaut
Ivor S. Douglas
Bengt Ga ˚rdlund
John C. Marshall
Andrew Rhodes
Statistical analysis plan
of PROWESS SHOCK study
Accepted: 6 July 2010
Published online: 6 August 2010
 Copyright jointly held by Springer and
ESICM 2010
Electronic supplementary material
The online version of this article
(doi:10.1007/s00134-010-1977-3) contains
supplementary material, which is available
to authorized users.
Dear Editor,
The steering committee (SC) of the
PROWESS SHOCK study has put in
place processes that should guarantee
independence and transparency to
resolve the controversies surrounding
the investigation and use of drotr-
ecogin alfa (activated), thus serving
the best interests of our patients [1].
The SC anticipated that the mor-
tality rates from sepsis may be
decreasing in response to improved
quality of care [2] with a consequent
inﬂuence on the sample size calcula-
tion for the PROWESS SHOCK
study. We have described the impact
of a falling placebo mortality rate and
how the sample size would need to be
changed to maintain 80% power to
detect a 20% relative mortality
reduction with drotrecogin alfa (acti-
vated) [2]. Accordingly, we employed
a conditional power design to resize
the study if aggregate mortality
observed for the ﬁrst 750 patients
was lower than the anticipated 31.5%
[1, 3].
Recent reports do indeed suggest
temporal improvements in sepsis
mortality. A multicenter demonstra-
tion project of a sepsis treatment
‘‘bundle’’ demonstrated a 5.4% abso-
lute decrease in hospital mortality in
the 15,022 subjects treated between
2005 and 2008 [4]. The australian and
new zealand intensive care (ANZIC)
research network investigators dem-
onstrated a reduction in hospital
mortality from 35.6% to 21.2%
(n = 7,250) over an 8-year period
ending in 2005 [5]. Recent trials have
also reported lower than expected
mortality. An international trial of
TAK-242, a TLR-4 antagonist,
enrolled 274 patients from 94 medical
centers with septic shock or sepsis
requiring mechanical ventilation and
noted a placebo 28-day mortality of
28% despite a sequential organ failure
assessment (SOFA) score over 8. The
predicted mortality for sample size
estimation was 40% [6]. A phase 2
trial of eritoran tetrasodium (E5564)
enrolled adults with severe sepsis.
The average predicted mortality was
53%, yet the observed 28-day mor-
tality was 24–25% [7].
On 12 May 2010 the SC reviewed
the aggregate baseline characteristics
and 28-day mortality for the ﬁrst 753
subjects in the PROWESS SHOCK
study. At baseline, the mean number
of organ failures was 3.5, all subjects
were vasopressor dependent through-
out the 17-h (mean) pre-enrollment
period, 72% had renal dysfunction,
and the (mean) total SOFA score was
9. The selected population therefore
has a higher disease severity com-
pared with PROWESS [8]. However,
the aggregate mortality was 27.6%.
Accordingly, the SC approved a
protocol-speciﬁed increase in sample
size from 1,500 to 1,696 subjects
(848 per group).
The analyses for the primary pub-
lication will be done by an
independent academic statistical
center [the Duke Clinical Research
Institute (DCRI), Drs. Kerry Lee and
Robert Califf]. Furthermore, the sta-
tistical analysis plan (SAP) has been
developed in collaboration with the
steering committee, the sponsor, and
the DCRI, and the ﬁnal plan submit-
ted to the Food and Drug
Administration (FDA) in February of
this year, prior to the ﬁrst interim
analysis by the data monitoring
committee (DMC). Furthermore, and
in accordance with recent calls for
publication of analysis plans in
advance of study completion, we are
attaching the entire SAP as a supple-
ment to this letter [9].
As of the end of June we have
enrolled 971 subjects into the trial,
with the majority being enrolled in
Europe. Based on the current rate of
enrollment and the assumption that
the DMC will allow the study to
continue to completion, we anticipate
that the study will be completed in
spring or summer 2011.
We wish to thank all our study
subjects and their families, as well as
our dedicated co-investigators and
research coordinators and the spon-
sor, Eli Lilly, for their participation,
support, and hard work on this
important study.
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